© 2017 by RareFundingTeam

Rare Disease News

Vertex is a global biotechnical company that focuses on developing and commercializing medicines to aid people with serious diseases to lead better lives. Vertex launched the “All in for CF” scholarship program to help people with cystic fibrosis and their immediate fa...

Chronic disease patients, who invest a great deal of time in the medical system, must apply pressure on legislators to improve access and transparency of the medical system.

June 26, 2017

Insurers are balking at the exorbitant price for a medication whose long-term clinical benefits have yet to be measured.

Despite its game changing technology, who will pay for CRISPR'S high cost? Will it be affordable; questions remain whether most insurance companies will pay for it.

Alexion Pharmaceuticals, Inc. presented new data displaying benefits of Soliris (eculizumab) treatment for patients with PNH, regardless of high disease activity (HDA) status, and for patients with hemolytic PNH and those with PNH with concurrent aplastic anemia (AA).

Takeda and Seattle Genetics announced promising results from its Phase 3 ECHELON-1 Clinical Trial that evaluated Adcetris in Frontline Advanced Hodgkin Lymphoma.

Please reload

Share your Rare Disease News

Send us rare disease news stories and we will post them on the site. Paste the web address into the message field and send.

Please reload

Follow Us
  • LinkedIn Social Icon
  • Facebook Basic Square
  • YouTube Social  Icon